Hub : Traits :

Relative age of first facial hair

660 significantly associated models · 100 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	10840905	11326788	1	1	9.6e-09	1.4e-36	1.8e-29	20	MASP2
2	1	243402721	244254617	1	1	5.9e-09	8.0e-10	1.0e+00	100	AKT3
3	2	27467598	28129391	2	2	1.0e-08	3.4e-08	1.0e+00	100	FNDC4 SUPT7L
4	2	222733842	224128542	1	1	2.2e-07	1.6e-13	5.4e-14	-4	RP11-16P6.1
5	2	232718042	234145080	1	1	8.2e-09	4.8e-08	3.6e-01	97	EIF4E2
6	3	10617048	12457119	2	2	3.5e-10	4.2e-13	1.2e-02	88	ATG7 VGLL4
7	3	49615624	52435860	13	3	1.2e-12	1.1e-10	4.0e-01	98	HEMK1 RBM6 TEX264
8	4	80561055	82578407	1	1	1.8e-07	5.8e-13	2.4e-11	14	C4orf22
9	4	94527983	95955095	1	1	1.3e-07	2.3e-08	1.0e+00	100	HPGDS
10	6	33856903	35362848	1	1	2.8e-08	4.3e-07	5.4e-01	98	C6orf106
11	6	41058968	42598371	3	9	1.2e-12	9.6e-11	1.0e+00	100	MED20 PRICKLE4
12	6	99192233	100719911	3	2	1.4e-10	1.2e-09	1.6e-02	84	CCNC RP1-199J3.5
13	6	104478130	106230491	2	1	3.3e-21	5.1e-35	1.8e-15	58	LIN28B
14	7	130101373	131880252	2	4	6.6e-24	4.7e-45	1.0e-07	86	MKLN1-AS2
15	10	17541614	19027696	1	1	1.3e-12	1.4e-09	4.3e-01	98	SLC39A12
16	10	64195778	65629712	2	1	3.7e-08	1.6e-07	2.3e-01	95	NRBF2
17	10	101975269	103362569	1	1	9.3e-08	1.3e-06	8.2e-01	100	RP11-179B2.2
18	11	29646947	31048683	1	1	2.3e-07	2.7e-05	1.2e-02	64	C11orf46
19	11	44038444	44580741	1	1	4.9e-17	1.4e-22	4.9e-07	74	ALX4
20	11	122058476	123525464	2	1	6.9e-15	5.7e-12	2.0e-02	89	C11orf63
21	12	64869118	66337026	1	1	4.8e-08	1.8e-09	9.0e-03	81	LEMD3
22	12	120502726	122037099	1	1	2.0e-08	3.9e-08	2.3e-01	95	SPPL3
23	14	24020127	25430242	4	1	1.0e-08	1.1e-09	2.3e-02	86	ADCY4
24	15	27662957	28535266	1	1	7.8e-11	3.5e-33	6.1e-24	29	HERC2
25	16	13697975	14759768	1	1	9.3e-14	1.5e-36	1.6e-24	34	RP11-65J21.3
26	16	88858246	90172696	16	9	1.0e-17	2.0e-14	NaN	NaN	AC092143.1 C16orf55 CDK10 DBNDD1 GAS8 MC1R SPATA33
27	17	42607368	46609918	25	2	2.6e-30	1.7e-28	1.0e+00	100	LRRC37A4P MRPL10
28	17	54272304	55667722	1	1	6.4e-13	8.5e-27	9.7e-16	44	MIR3614
29	17	63385561	64438011	1	1	2.0e-07	7.1e-09	8.3e-03	79	CCDC46
30	19	3293593	3797612	1	1	6.0e-08	2.7e-06	5.3e-01	98	C19orf28
31	21	39849553	41383143	4	1	7.4e-09	1.8e-08	1.2e-01	92	PSMG1

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Hair Pigment	149.98	19	14	31.1	0.65	7.3e-04	AC092143.1 ALX4 C16orf55 C4orf22 C6orf106 CDK10 DBNDD1 FNDC4 GAS8 HERC2 LRRC37A4P MASP2 MC1R MED20 MIR3614 MRPL10 SLC39A12 SPATA33 VGLL4
Tanning	117.05	10	10	22.2	-0.81	1.5e-04	AC092143.1 C16orf55 CDK10 DBNDD1 FNDC4 GAS8 HERC2 MC1R MED20 SPATA33
Blood Red Count	14.96	11	8	17.8	-0.62	4.8e-03	AC092143.1 C4orf22 C6orf106 CDK10 FNDC4 LRRC37A4P MC1R MED20 NRBF2 PRICKLE4 SUPT7L
Relative age voice broke	10.39	19	6	13.3	0.98	1.3e-16	ALX4 C11orf63 C16orf55 DBNDD1 EIF4E2 GAS8 HEMK1 HPGDS LIN28B LRRC37A4P MED20 MKLN1-AS2 NRBF2 PRICKLE4 PSMG1 RP11-65J21.3 RP1-199J3.5 SPPL3 TEX264
Triglycerides	9.42	3	3	6.7	0.00	1.0e+00	FNDC4 NRBF2 SUPT7L
Age when periods started (menarche)	8.49	16	9	20.0	0.93	2.1e-10	AKT3 C11orf63 C6orf106 HEMK1 HPGDS LIN28B LRRC37A4P MED20 NRBF2 PRICKLE4 PSMG1 RBM6 RP11-179B2.2 RP11-65J21.3 SUPT7L TEX264
Hair/balding pattern: Pattern 4	6.73	11	5	11.1	-0.28	3.3e-01	ATG7 C4orf22 CCDC46 DBNDD1 GAS8 LRRC37A4P MASP2 MIR3614 MKLN1-AS2 SPATA33 VGLL4
Basal cell carcinoma (self-reported)	5.82	5	5	11.1	0.99	4.3e-05	C16orf55 CDK10 DBNDD1 GAS8 SPATA33
Whole body water mass	4.30	14	11	24.4	0.46	6.3e-02	ADCY4 C6orf106 CDK10 FNDC4 LEMD3 LIN28B MASP2 MED20 PRICKLE4 RBM6 RP11-179B2.2 RP11-65J21.3 SPPL3 SUPT7L
Trunk predicted mass	4.27	15	11	24.4	0.48	4.5e-02	ADCY4 C6orf106 CDK10 EIF4E2 FNDC4 LEMD3 LIN28B MASP2 MED20 PRICKLE4 RBM6 RP11-179B2.2 RP11-65J21.3 SPPL3 SUPT7L
Whole body fat-free mass	4.27	15	11	24.4	0.49	3.8e-02	ADCY4 C6orf106 CDK10 EIF4E2 FNDC4 LEMD3 LIN28B MASP2 MED20 PRICKLE4 RBM6 RP11-179B2.2 RP11-65J21.3 SPPL3 SUPT7L
Trunk fat-free mass	4.25	15	11	24.4	0.47	4.7e-02	ADCY4 C6orf106 CDK10 EIF4E2 FNDC4 LEMD3 LIN28B MASP2 MED20 PRICKLE4 RBM6 RP11-179B2.2 RP11-65J21.3 SPPL3 SUPT7L
Basal metabolic rate	4.23	16	10	22.2	0.43	5.7e-02	ADCY4 C6orf106 CDK10 EIF4E2 FNDC4 GAS8 LEMD3 LIN28B MASP2 MED20 PRICKLE4 RBM6 RP11-179B2.2 RP11-65J21.3 SPPL3 SUPT7L
Arm fat-free mass (right)	4.13	13	11	24.4	0.53	3.3e-02	ADCY4 C6orf106 CDK10 EIF4E2 FNDC4 LEMD3 MASP2 MED20 PRICKLE4 RBM6 RP11-179B2.2 RP11-65J21.3 SUPT7L
Arm fat-free mass (left)	4.07	13	10	22.2	0.53	3.6e-02	ADCY4 C6orf106 CDK10 EIF4E2 FNDC4 LEMD3 MASP2 MED20 PRICKLE4 RBM6 RP11-179B2.2 RP11-65J21.3 SUPT7L
Arm predicted mass (left)	4.06	13	11	24.4	0.53	3.5e-02	ADCY4 C6orf106 CDK10 EIF4E2 FNDC4 LEMD3 MASP2 MED20 PRICKLE4 RBM6 RP11-179B2.2 RP11-65J21.3 SUPT7L
Arm predicted mass (right)	4.03	13	9	20.0	0.52	3.7e-02	ADCY4 C6orf106 CDK10 EIF4E2 FNDC4 LEMD3 MASP2 MED20 PRICKLE4 RBM6 RP11-179B2.2 RP11-65J21.3 SUPT7L
Leg predicted mass (right)	4.02	12	9	20.0	0.52	3.9e-02	ADCY4 C6orf106 CDK10 FNDC4 LEMD3 LIN28B MASP2 MED20 PRICKLE4 RBM6 RP11-179B2.2 SUPT7L
Leg fat-free mass (right)	4.01	12	9	20.0	0.52	3.7e-02	ADCY4 C6orf106 CDK10 FNDC4 LEMD3 LIN28B MASP2 MED20 PRICKLE4 RBM6 RP11-179B2.2 SUPT7L
Leg predicted mass (left)	3.99	13	9	20.0	0.51	3.9e-02	ADCY4 C6orf106 CDK10 FNDC4 LEMD3 LIN28B MASP2 MED20 PRICKLE4 RBM6 RP11-179B2.2 SPPL3 SUPT7L
Leg fat-free mass (left)	3.97	13	9	20.0	0.50	4.0e-02	ADCY4 C6orf106 CDK10 FNDC4 LEMD3 LIN28B MASP2 MED20 PRICKLE4 RBM6 RP11-179B2.2 SPPL3 SUPT7L
Pulse rate, automated reading	3.76	10	6	13.3	-0.60	5.4e-03	C4orf22 C6orf106 EIF4E2 FNDC4 MED20 MKLN1-AS2 PRICKLE4 PSMG1 RP1-199J3.5 SUPT7L
Height	3.73	26	23	51.1	0.26	1.4e-01	ADCY4 C11orf63 C16orf55 C19orf28 C6orf106 CDK10 DBNDD1 EIF4E2 FNDC4 GAS8 HEMK1 LEMD3 LIN28B LRRC37A4P MASP2 MED20 MIR3614 MKLN1-AS2 NRBF2 PRICKLE4 RP11-179B2.2 RP11-65J21.3 SPATA33 SPPL3 SUPT7L TEX264
Standing height	3.65	23	21	46.7	0.33	8.5e-02	ADCY4 C11orf63 C16orf55 C19orf28 C6orf106 CDK10 DBNDD1 EIF4E2 FNDC4 GAS8 HEMK1 LEMD3 LIN28B LRRC37A4P MASP2 MED20 NRBF2 PRICKLE4 RP11-179B2.2 RP11-65J21.3 SPPL3 SUPT7L TEX264
Weight	3.49	13	7	15.6	0.10	6.9e-01	ADCY4 C16orf55 C6orf106 DBNDD1 EIF4E2 FNDC4 GAS8 MASP2 MED20 PRICKLE4 RBM6 RP11-179B2.2 SUPT7L
Blood Platelet Count	3.35	13	6	13.3	0.10	7.4e-01	C6orf106 CCDC46 EIF4E2 FNDC4 HPGDS LRRC37A4P MED20 MRPL10 NRBF2 PSMG1 RP11-179B2.2 SPPL3 SUPT7L
Forced expiratory volume in 1-second (FEV1), predicted	3.33	5	2	4.4	0.39	5.2e-01	C6orf106 DBNDD1 GAS8 LEMD3 LIN28B
Hair/balding pattern: Pattern 3	3.28	3	2	4.4	0.00	1.0e+00	C4orf22 LRRC37A4P MIR3614
Impedance of arm (left)	3.28	13	8	17.8	0.03	9.2e-01	AC092143.1 CDK10 DBNDD1 FNDC4 LIN28B LRRC37A4P MASP2 MC1R NRBF2 RBM6 RP11-179B2.2 SUPT7L TEX264
High cholesterol (Self-reported)	3.27	2	2	4.4	0.00	1.0e+00	FNDC4 SUPT7L
Impedance of whole body	3.26	15	8	17.8	-0.06	8.3e-01	AC092143.1 CDK10 DBNDD1 FNDC4 GAS8 LIN28B LRRC37A4P MASP2 MC1R MED20 NRBF2 RBM6 RP11-179B2.2 SUPT7L TEX264
Average weekly beer plus cider intake	3.21	4	1	2.2	0.30	5.1e-01	NRBF2 PRICKLE4 PSMG1 RBM6
Alcohol intake frequency.	3.14	3	3	6.7	0.00	1.0e+00	FNDC4 LRRC37A4P SUPT7L
Impedance of arm (right)	3.10	10	8	17.8	0.22	5.4e-01	DBNDD1 FNDC4 LIN28B LRRC37A4P MASP2 NRBF2 RBM6 RP11-179B2.2 SUPT7L TEX264
Had menopause	3.08	2	0	0.0	0.00	1.0e+00	DBNDD1 MC1R
Fasting Glucose	2.98	2	2	4.4	0.00	1.0e+00	FNDC4 SUPT7L
Trunk fat mass	2.98	14	6	13.3	0.05	8.6e-01	C11orf63 C16orf55 C6orf106 DBNDD1 EIF4E2 GAS8 LIN28B LRRC37A4P MASP2 MC1R MED20 PSMG1 RBM6 RP11-179B2.2
Medication: Omeprazole (e.g. Zanprol)	2.97	2	0	0.0	-0.99	6.5e-04	MED20 PRICKLE4
Gout (self-reported)	2.91	2	1	2.2	0.00	1.0e+00	FNDC4 SUPT7L
Hip circumference	2.90	11	5	11.1	0.22	4.5e-01	C6orf106 DBNDD1 FNDC4 GAS8 MASP2 MED20 PRICKLE4 PSMG1 RBM6 RP11-179B2.2 SUPT7L
Impedance of leg (left)	2.79	13	5	11.1	-0.16	5.6e-01	C16orf55 C6orf106 DBNDD1 FNDC4 GAS8 LIN28B LRRC37A4P MASP2 MC1R MED20 RP11-179B2.2 SUPT7L TEX264
Medication: Allopurinol	2.78	2	1	2.2	0.00	1.0e+00	FNDC4 SUPT7L
Impedance of leg (right)	2.76	12	5	11.1	-0.08	7.8e-01	C16orf55 C6orf106 DBNDD1 FNDC4 GAS8 LIN28B LRRC37A4P MASP2 MED20 RP11-179B2.2 SUPT7L TEX264
Mineral and other dietary supplements	2.76	3	0	0.0	0.00	1.0e+00	MED20 NRBF2 PRICKLE4
Comparative height size at age 10	2.71	12	9	20.0	-0.09	7.9e-01	ADCY4 C16orf55 C6orf106 CDK10 EIF4E2 FNDC4 GAS8 LRRC37A4P MASP2 RP11-179B2.2 RP1-199J3.5 SUPT7L
Systolic Blood Pressure	2.69	9	6	13.3	0.23	5.0e-01	C11orf46 C4orf22 DBNDD1 FNDC4 LRRC37A4P MC1R MKLN1-AS2 NRBF2 VGLL4
Sitting height	2.69	18	11	24.4	0.10	6.8e-01	ADCY4 AKT3 C16orf55 C6orf106 CDK10 DBNDD1 EIF4E2 FNDC4 GAS8 LEMD3 LRRC37A4P MASP2 MED20 PRICKLE4 RP11-179B2.2 RP11-65J21.3 SUPT7L VGLL4
Ever had bowel cancer screening	2.57	1	1	2.2	0.00	1.0e+00	PRICKLE4
Trunk fat percentage	2.51	10	6	13.3	-0.49	1.1e-01	AC092143.1 C11orf63 C16orf55 C6orf106 DBNDD1 GAS8 LRRC37A4P MC1R PSMG1 RBM6
Whole body fat mass	2.51	9	3	6.7	0.15	6.4e-01	C11orf63 C6orf106 DBNDD1 GAS8 MASP2 MED20 PSMG1 RBM6 RP11-179B2.2
Medication for cholesterol	2.49	3	2	4.4	0.00	1.0e+00	C4orf22 FNDC4 MC1R
Hair/balding pattern: Pattern 2	2.44	3	1	2.2	0.00	1.0e+00	C4orf22 CCDC46 LRRC37A4P
Lung FVC	2.40	7	5	11.1	-0.84	1.9e-02	C6orf106 CCDC46 EIF4E2 LIN28B LRRC37A4P SPPL3 TEX264
Taking other prescription medications	2.39	1	0	0.0	0.00	1.0e+00	RBM6
Age at First Birth	2.38	4	1	2.2	0.46	5.4e-01	CDK10 DBNDD1 RBM6 RP11-179B2.2
Medication: Blood pressure	2.38	5	2	4.4	-0.20	7.5e-01	C4orf22 LRRC37A4P MC1R NRBF2 SPATA33
Chronotype (morning person)	2.32	4	1	2.2	0.59	9.2e-02	HEMK1 MED20 PRICKLE4 RBM6
Arm fat mass (left)	2.32	8	3	6.7	0.50	1.2e-01	C6orf106 FNDC4 MASP2 MED20 PSMG1 RBM6 RP11-179B2.2 SUPT7L
Arm fat mass (right)	2.25	8	3	6.7	0.49	1.2e-01	C6orf106 FNDC4 MASP2 MED20 PSMG1 RBM6 RP11-179B2.2 SUPT7L
High blood pressure	2.24	6	2	4.4	0.39	3.9e-01	C4orf22 CDK10 DBNDD1 MC1R NRBF2 SPATA33
Number of treatments/medications taken	2.23	3	0	0.0	0.00	1.0e+00	FNDC4 LIN28B RBM6
Leg fat mass (left)	2.22	8	2	4.4	0.53	1.8e-01	C6orf106 FNDC4 MASP2 NRBF2 PSMG1 RBM6 RP11-179B2.2 SUPT7L
Systolic blood pressure, automated reading	2.20	4	3	6.7	-0.03	9.5e-01	C4orf22 LRRC37A4P MKLN1-AS2 VGLL4
Number of operations (self-reported)	2.15	1	0	0.0	0.00	1.0e+00	LIN28B
Supplements: Zinc	2.14	1	0	0.0	0.00	1.0e+00	NRBF2
Leg fat mass (right)	2.14	7	2	4.4	0.55	2.0e-01	C6orf106 FNDC4 MASP2 NRBF2 PSMG1 RBM6 RP11-179B2.2
Hypertension (Self-reported)	2.13	5	2	4.4	0.20	7.4e-01	C4orf22 CDK10 DBNDD1 NRBF2 SPATA33
Blood White Count	2.11	9	6	13.3	-0.07	8.6e-01	AKT3 CDK10 FNDC4 LRRC37A4P MC1R NRBF2 RBM6 SLC39A12 SUPT7L
Vascular/heart problems diagnosed by doctor	2.10	5	1	2.2	-0.32	6.0e-01	C4orf22 DBNDD1 MC1R NRBF2 SPATA33
Cardiovascular Disease	2.06	6	2	4.4	0.34	5.1e-01	C11orf46 C4orf22 FNDC4 NRBF2 SPATA33 VGLL4
Pulse rate	2.06	2	1	2.2	0.00	1.0e+00	FNDC4 MKLN1-AS2
Medication: Atenolol	2.03	2	0	0.0	0.00	1.0e+00	C4orf22 DBNDD1
Ever unenthusiastic/disinterested for a whole week	2.03	1	0	0.0	0.00	1.0e+00	LRRC37A4P
Wheeze or whistling in the chest in last year	2.03	2	1	2.2	0.00	1.0e+00	CCDC46 RBM6
Cholesterol lowering medication	2.03	2	1	2.2	0.00	1.0e+00	FNDC4 SUPT7L
Forced vital capacity (FVC)	2.02	7	3	6.7	-0.33	4.7e-01	C16orf55 C6orf106 DBNDD1 LEMD3 LRRC37A4P RP11-179B2.2 RP11-65J21.3
Body fat percentage	1.96	8	3	6.7	-0.35	3.5e-01	C11orf63 C6orf106 DBNDD1 GAS8 LRRC37A4P MC1R PSMG1 RBM6
Supplements: Calcium	1.96	1	0	0.0	0.00	1.0e+00	NRBF2
Neuroticism	1.95	2	1	2.2	0.00	1.0e+00	LIN28B LRRC37A4P
Forced expiratory volume in 1-second (FEV1)	1.95	5	3	6.7	-0.04	9.5e-01	C6orf106 LEMD3 LRRC37A4P RP11-179B2.2 RP11-65J21.3
Worry too long after embarrassment	1.95	4	1	2.2	0.98	1.7e-02	C16orf55 DBNDD1 GAS8 LRRC37A4P
Other serious medical condition/disability diagnosed by doctor	1.91	1	0	0.0	0.00	1.0e+00	PRICKLE4
Illnesses of father: High blood pressure	1.91	1	0	0.0	0.00	1.0e+00	C4orf22
Forced vital capacity (FVC), Best measure	1.89	5	3	6.7	-0.11	8.6e-01	C6orf106 LEMD3 LRRC37A4P RP11-179B2.2 RP11-65J21.3
Miserableness	1.89	2	1	2.2	0.00	1.0e+00	LRRC37A4P RBM6
Waist Hip Ratio (WHR)	1.87	6	3	6.7	-0.38	2.7e-01	C6orf106 HEMK1 LRRC37A4P MED20 PRICKLE4 VGLL4
Vitamin and mineral supplements	1.87	1	0	0.0	0.00	1.0e+00	NRBF2
Bipolar Disorder (2018)	1.85	2	0	0.0	0.00	1.0e+00	FNDC4 SPATA33
Sensitivity / hurt feelings	1.84	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Alcohol usually taken with meals	1.84	2	0	0.0	0.00	1.0e+00	NRBF2 PRICKLE4
Neuroticism (Nagel 2018)	1.82	2	1	2.2	0.00	1.0e+00	LIN28B LRRC37A4P
Waist circumference	1.81	5	2	4.4	0.53	3.6e-01	C6orf106 FNDC4 PSMG1 RBM6 RP11-179B2.2
Peak expiratory flow (PEF)	1.81	2	2	4.4	0.00	1.0e+00	LRRC37A4P RP11-65J21.3
Hearing difficulty/problems: Yes	1.79	1	0	0.0	0.00	1.0e+00	AKT3
Number of live births	1.79	2	0	0.0	0.00	1.0e+00	DBNDD1 LRRC37A4P
Medication: Cholesterol lowering	1.78	1	1	2.2	0.00	1.0e+00	FNDC4
Medication: Paracetamol	1.78	1	1	2.2	0.00	1.0e+00	LRRC37A4P
BMI	1.77	11	7	15.6	0.32	3.3e-01	AKT3 C4orf22 C6orf106 FNDC4 MASP2 MED20 NRBF2 PSMG1 RBM6 RP11-179B2.2 SUPT7L
Comparative body size at age 10	1.77	4	2	4.4	-0.64	3.6e-01	C16orf55 LIN28B SPPL3 VGLL4
Medication: Lisinopril	1.75	1	0	0.0	0.00	1.0e+00	CDK10
Alcohol intake versus 10 years previously	1.74	3	1	2.2	0.00	1.0e+00	FNDC4 RBM6 SUPT7L
Supplements: Vitamin C	1.74	1	0	0.0	0.00	1.0e+00	PRICKLE4
Medication: Atorvastatin	1.74	2	1	2.2	0.00	1.0e+00	FNDC4 SUPT7L
Asthma	1.72	3	0	0.0	0.00	1.0e+00	C16orf55 GAS8 SPATA33
Forced expiratory volume in 1-second (FEV1), Best measure	1.72	3	1	2.2	0.00	1.0e+00	C6orf106 LRRC37A4P RP11-65J21.3
Mood swings	1.72	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Schizophrenia (2014)	1.70	3	0	0.0	0.00	1.0e+00	AKT3 LIN28B SPATA33
Friendships satisfaction	1.70	1	0	0.0	0.00	1.0e+00	RP11-65J21.3
Ever depressed for a whole week	1.69	2	0	0.0	0.00	1.0e+00	AKT3 HEMK1
Smoking Status	1.68	1	0	0.0	0.00	1.0e+00	DBNDD1
Respiratory disease	1.68	3	0	0.0	0.00	1.0e+00	GAS8 PSMG1 SPATA33
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.68	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Allergy or Eczema	1.67	4	2	4.4	0.51	4.9e-01	C6orf106 FNDC4 PSMG1 SPPL3
Asthma (self-reported)	1.67	3	0	0.0	0.00	1.0e+00	C16orf55 GAS8 SPATA33
Bipolar Disorder or Schizophrenia	1.66	3	2	4.4	0.00	1.0e+00	AKT3 SPATA33 SUPT7L
Type 2 Diabetes (T2D) (2018)	1.66	1	1	2.2	0.00	1.0e+00	FNDC4
Body mass index (BMI)	1.63	8	5	11.1	0.33	4.3e-01	C6orf106 FNDC4 MASP2 NRBF2 PSMG1 RBM6 RP11-179B2.2 SUPT7L
Number of self-reported non-cancer illnesses	1.61	1	1	2.2	0.00	1.0e+00	FNDC4
Arm fat percentage (left)	1.59	3	2	4.4	0.00	1.0e+00	C6orf106 PSMG1 RBM6
Depressed Affect (Nagel 2018)	1.58	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Diastolic blood pressure, automated reading	1.58	3	2	4.4	0.00	1.0e+00	C4orf22 CCDC46 NRBF2
Hand grip strength (right)	1.57	3	1	2.2	0.00	1.0e+00	C6orf106 LIN28B LRRC37A4P
Medication: Paracetamol	1.57	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Heel T-Score	1.56	9	8	17.8	-0.80	1.0e-02	ADCY4 C11orf63 C16orf55 DBNDD1 GAS8 LIN28B LRRC37A4P MASP2 VGLL4
Medication: Simvastatin	1.56	1	1	2.2	0.00	1.0e+00	FNDC4
Medication for pain relief, constipation, heartburn	1.54	2	0	0.0	0.00	1.0e+00	C6orf106 LRRC37A4P
Diabetes diagnosed by doctor	1.54	1	1	2.2	0.00	1.0e+00	FNDC4
Hand grip strength (left)	1.52	3	1	2.2	0.00	1.0e+00	CDK10 LIN28B LRRC37A4P
Ulcerative Colitis	1.50	1	0	0.0	0.00	1.0e+00	RBM6
LDL Cholesterol	1.49	2	1	2.2	0.00	1.0e+00	C6orf106 FNDC4
Diabetes (self-reported)	1.45	1	1	2.2	0.00	1.0e+00	FNDC4
Arm fat percentage (right)	1.45	3	2	4.4	0.00	1.0e+00	C6orf106 PSMG1 RBM6
Medication: Blood pressure	1.44	1	1	2.2	0.00	1.0e+00	C4orf22
Neuroticism score	1.43	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Hearing difficulty/problems with background noise	1.42	3	0	0.0	0.00	1.0e+00	LIN28B LRRC37A4P VGLL4
Age at first live birth	1.42	1	0	0.0	0.00	1.0e+00	RBM6
Handedness (chirality/laterality): Left-handed	1.42	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Guilty feelings	1.41	2	1	2.2	0.00	1.0e+00	LIN28B LRRC37A4P
Worry (Nagel 2018)	1.40	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Supplements: Glucosamine	1.40	1	0	0.0	0.00	1.0e+00	NRBF2
Qualifications: A levels/AS levels or equivalent	1.40	3	1	2.2	0.00	1.0e+00	LRRC37A4P NRBF2 RBM6
Leg fat percentage (left)	1.40	4	3	6.7	0.38	6.2e-01	C6orf106 NRBF2 PSMG1 RBM6
Ovarian Cancer	1.39	1	1	2.2	0.00	1.0e+00	LRRC37A4P
High blood pressure (mother)	1.39	1	0	0.0	0.00	1.0e+00	C4orf22
Allergy	1.38	4	0	0.0	-0.58	4.2e-01	C6orf106 PSMG1 RBM6 SPPL3
Diabetes (father)	1.37	1	0	0.0	0.00	1.0e+00	FNDC4
Multivitamins +/- minerals	1.36	1	1	2.2	0.00	1.0e+00	NRBF2
Average weekly champagne plus white wine intake	1.36	1	0	0.0	0.00	1.0e+00	LRRC37A4P
Schizophrenia (2018)	1.34	2	1	2.2	0.00	1.0e+00	AKT3 LIN28B
Frequency of tenseness / restlessness in last 2 weeks	1.34	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Leg fat percentage (right)	1.32	4	2	4.4	0.38	6.2e-01	C6orf106 NRBF2 PSMG1 RBM6
Age at last live birth	1.32	1	1	2.2	0.00	1.0e+00	RBM6
Average weekly red wine intake	1.31	1	0	0.0	0.00	1.0e+00	NRBF2
Back pain experienced in last month	1.31	1	0	0.0	0.00	1.0e+00	C6orf106
Overall health rating	1.29	2	0	0.0	0.00	1.0e+00	C6orf106 RBM6
Heel bone mineral density (BMD) T-score, automated (right)	1.28	2	0	0.0	0.00	1.0e+00	DBNDD1 LRRC37A4P
Loneliness, isolation	1.28	1	0	0.0	0.00	1.0e+00	LRRC37A4P
Qualifications: College or University degree	1.27	4	2	4.4	-0.45	5.5e-01	CDK10 HPGDS LRRC37A4P RBM6
Hayfever, allergic rhinitis or eczema	1.26	3	1	2.2	0.00	1.0e+00	C6orf106 SPPL3 TEX264
Medication for cholesterol, blood pressure or diabetes	1.26	2	0	0.0	0.00	1.0e+00	C4orf22 FNDC4
Irritable Bowel Disease (IBD)	1.25	2	2	4.4	0.00	1.0e+00	FNDC4 RBM6
Ulcerative Colitis (UC)	1.25	1	0	0.0	0.00	1.0e+00	RBM6
Heel bone mineral density (BMD) T-score, automated (left)	1.25	2	0	0.0	0.00	1.0e+00	LIN28B LRRC37A4P
Blood Eosinophil Count	1.24	7	5	11.1	0.20	6.7e-01	CCDC46 HEMK1 LRRC37A4P RBM6 SPPL3 SUPT7L TEX264
Medication: Metformin	1.24	1	1	2.2	0.00	1.0e+00	FNDC4
Ever highly irritable/argumentative for 2 days	1.21	1	0	0.0	0.00	1.0e+00	RBM6
Blood clot in the leg (DVT)	1.21	1	0	0.0	0.00	1.0e+00	NRBF2
Qualifications: None of the above	1.20	2	0	0.0	0.00	1.0e+00	NRBF2 RBM6
Primary Biliary Cirrhosis	1.19	1	0	0.0	0.00	1.0e+00	LRRC37A4P
Neuroticism (2016)	1.18	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Pain experienced in last month	1.18	1	0	0.0	0.00	1.0e+00	C6orf106
Headache pain in last month	1.17	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Risk taking	1.17	1	1	2.2	0.00	1.0e+00	AKT3
Mouth/teeth dental problems: Mouth ulcers	1.15	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Intelligence (Savage-Jansen 2018)	1.13	4	1	2.2	-0.34	6.6e-01	LRRC37A4P NRBF2 PSMG1 RBM6
HDL Cholesterol	1.13	1	1	2.2	0.00	1.0e+00	C6orf106
Nervous feelings	1.13	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Crohns Disease (2017)	1.11	2	1	2.2	0.00	1.0e+00	FNDC4 RBM6
Myopia	1.11	1	0	0.0	0.00	1.0e+00	EIF4E2
Heart attack/myocardial infarction (self-reported)	1.08	1	0	0.0	0.00	1.0e+00	C6orf106
Breast Cancer	1.06	2	1	2.2	0.00	1.0e+00	AC092143.1 LRRC37A4P
Fed-up feelings	1.06	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Verbal and Numeric Reasoning (VNR)	1.05	2	1	2.2	0.00	1.0e+00	LRRC37A4P RBM6
Lung FEV1/FVC ratio	1.03	5	3	6.7	0.30	6.2e-01	C6orf106 HEMK1 LRRC37A4P NRBF2 VGLL4
Heart attack	1.02	1	0	0.0	0.00	1.0e+00	C6orf106
Irritability	1.02	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Fluid intelligence score	1.01	1	1	2.2	0.00	1.0e+00	RBM6
Deep venous thrombosis (DVT) (self-reported)	0.98	1	0	0.0	0.00	1.0e+00	NRBF2
Worrier / anxious feelings	0.80	1	1	2.2	0.00	1.0e+00	LRRC37A4P

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Uterus	6	1.06	3.0
GTEx	Brain Hippocampus	5	0.95	2.9
GTEx	Brain Hypothalamus	8	1.36	2.9
GTEx	Small Intestine Terminal Ileum	6	1.30	2.9
GTEx	Artery Coronary	11	0.93	2.7
GTEx	Brain Cortex	10	0.97	2.7
GTEx	Brain Nucleus accumbens basal ganglia	7	0.81	2.7
GTEx	Brain Putamen basal ganglia	6	0.96	2.7
GTEx	Ovary	7	0.77	2.7
GTEx	Esophagus Gastroesophageal Junction	11	0.76	2.6
GTEx	Vagina	5	0.79	2.6
GTEx	Brain Frontal Cortex BA9	6	0.65	2.5
GTEx	Breast Mammary Tissue (Male)	10	0.84	2.5
GTEx	Cells EBV-transformed lymphocytes	11	0.77	2.5
GTEx	Stomach	13	0.89	2.5
GTEx	Breast Mammary Tissue (Female)	12	0.73	2.4
GTEx	Colon Sigmoid	10	0.68	2.4
GTEx	Colon Transverse	13	0.63	2.4
GTEx	Heart Atrial Appendage	11	0.70	2.4
GTEx	Heart Left Ventricle	11	0.72	2.4
GTEx	Liver	6	0.84	2.4
GTEx	Prostate	6	0.72	2.4
GTEx	Adipose Visceral Omentum	11	0.54	2.3
GTEx	Brain Caudate basal ganglia	6	0.65	2.3
GTEx	Brain Cerebellar Hemisphere	9	0.60	2.3
GTEx	Breast Mammary Tissue	9	0.46	2.3
GTEx	Pancreas	12	0.74	2.3
GTEx	Pituitary	5	0.45	2.3
GTEx	Skin Not Sun Exposed Suprapubic	13	0.53	2.3
GTEx	Adipose Subcutaneous	16	0.46	2.2
GTEx	Adrenal Gland	7	0.48	2.2
GTEx	Brain Cerebellum	11	0.55	2.2
GTEx	Esophagus Muscularis	13	0.40	2.2
GTEx	Lung	14	0.49	2.2
GTEx	Spleen	9	0.64	2.2
GTEx	Testis	19	0.60	2.2
GTEx	Thyroid	17	0.43	2.2
The Cancer Genome Atlas	Esophageal Carcinoma	3	0.44	2.2
GTEx	Artery Aorta	13	0.44	2.1
GTEx	Cells Transformed fibroblasts	14	0.33	2.1
GTEx	Esophagus Mucosa	15	0.45	2.1
GTEx	Muscle Skeletal	13	0.45	2.1
GTEx	Skin Sun Exposed Lower leg	11	0.30	2.1
GTEx	Whole Blood	9	0.45	2.1
The Cancer Genome Atlas	Glioblastoma Multiforme	5	0.49	2.1
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	8	0.60	2.1
The Cancer Genome Atlas	Rectum Adenocarcinoma	3	0.43	2.1
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	2	0.39	2.1
GTEx	Artery Tibial	13	0.35	2.0
GTEx	Nerve Tibial	19	0.44	2.0
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	3	0.27	2.0
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	4	0.36	2.0
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	6	0.38	2.0
The Cancer Genome Atlas	Soft Tissue Sarcoma	5	0.47	2.0
The Cancer Genome Atlas	Stomach Adenocarcinoma	6	0.36	2.0
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	3	0.18	1.9
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	14	0.34	1.9
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	7	0.34	1.9
The Cancer Genome Atlas	Brain Lower Grade Glioma	10	0.23	1.9
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	7	0.28	1.9
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	4	0.24	1.9
The Cancer Genome Atlas	Prostate Adenocarcinoma	17	0.37	1.9
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.19	1.9
The Cancer Genome Atlas	Testicular Germ Cell Tumors	3	0.23	1.9
NTR	Blood	4	0.17	1.8
ROSMAP	Brain Pre-frontal Cortex	6	0.14	1.8
CommonMind	Brain Pre-frontal Cortex	15	0.28	1.8
The Cancer Genome Atlas	Breast Invasive Carcinoma	12	0.27	1.8
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	6	0.22	1.8
The Cancer Genome Atlas	Lung Adenocarcinoma	6	0.20	1.8
The Cancer Genome Atlas	Thyroid Carcinoma	16	0.31	1.8
METSIM	Adipose	7	0.15	1.7
YFS	Blood	5	0.11	1.7
The Cancer Genome Atlas	Colon Adenocarcinoma	3	0.15	1.7